Synapse - Advanced Practice Providers

Results (101)

Cardio-oncology in the COVID-19 era

Book Section

Feldman, S.; Jang, K.; Smith, D.; Copeland-Halperin, R. S.
In Steingart, R. M.; Liu, J. E. (Eds.) Atlas of Imaging in Cardio-Oncology: Case-Based Study Guide (2021)

Fulltext@MSK | Save

Zanubrutinib, obinutuzumab, and venetoclax in chronic lymphocytic leukemia: Early MRD kinetics define a high-risk patient cohort with delayed bone marrow undetectable MRD and earlier post-treatment MRD recurrence

Meeting Abstract

Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E. P.; Barnes, J. A.; Hamilton, A.; more...
Blood (2021)

Fulltext@MSK | Save

Outcomes of chronic lymphocytic leukemia and Richter Transformation following discontinuation of noncovalent Bruton's Tyrosine Kinase inhibitors

Meeting Abstract

Thompson, M. C.; Coombs, C. C.; Roeker, L. E.; Pagel, J. M.; Jensen, J. L.; Battiato, K. E.; Fox, Y.; Meyer, K.; Bailey, N.; Rhodes, J. M.; more...
Blood (2021)

Fulltext@MSK | Save

Addressing a new challenge in chronic lymphocytic leukemia: Outcomes of therapies after exposure to both a covalent Bruton's Tyrosine Kinase Inhibitor and venetoclax

Meeting Abstract

Thompson, M. C.; Roeker, L. E.; Coombs, C. C.; Jensen, J. L.; Kamdar, M.; Skarbnik, A.; Pagel, J. M.; Bailey, N.; Pu, J. J.; Jacobs, R.; more...
Blood (2021)

Fulltext@MSK | Save

Timing and immune status after cellular therapies predict response to COVID-19 vaccines

Meeting Abstract

Tamari, R.; Politikos, I.; Knorr, D.; Vardhana, S.; Young, J.; Marcello, L.; Doddi, S.; Devlin, S. M.; Ramanathan, L.; Pessin, M. S.; more...
Blood (2021)

Fulltext@MSK | Save

The intestinal microbiota correlates with response and toxicity after CAR T cell therapy in patients with B-cell malignancies

Meeting Abstract

Smith, M.; Dai, A.; Ghilardi, G.; Amelsberg, K.; Devlin, S. M.; Pajarillo, R.; Slingerland, J. B.; Beghi, S.; Herrera, P. S.; Giardina, P. A.; more...
Blood (2021)

Fulltext@MSK | Save

A phase 2 study evaluating the addition of ublituximab and umbralisib (U2) to ibrutinib in patients with chronic lymphocytic leukemia (CLL): A minimal residual disease(MRD)-driven, time-limited approach

Meeting Abstract

Roeker, L. E.; Leslie, L. A.; Soumerai, J. D.; Falco, V.; Panton, G.; Zelenetz, A. D.; Falchi, L.; Park, J. H.; Pena-Velasquez, C.; Lebowitz, S.; more...
Blood (2021)

Fulltext@MSK | Save

Phase I first-in-class trial of MCARH109, a G protein coupled receptor class C group 5 member D (GPRC5D) targeted CAR T cell therapy in patients with relapsed or refractory multiple myeloma

Meeting Abstract

Mailankody, S.; Diamonte, C.; Fitzgerald, L.; Kane, P.; Wang, X.; Sikder, D. S.; Senechal, B.; Bermudez, V. P.; Frias, D.; Morgan, J.; more...
Blood (2021)

Fulltext@MSK | Save

Preliminary safety and efficacy from a multicenter, investigator-initiated phase II study in untreated TP53 mutant mantle cell lymphoma with zanubrutinib, obinutuzumab, and venetoclax (BOVen)

Meeting Abstract

Kumar, A.; Soumerai, J. D.; Abramson, J. S.; Batlevi, C. L.; Chadha, P.; Dogan, A.; Falchi, L.; Flaherty, K.; Friedman, C.; Grieve, C.; more...
Blood (2021)

Fulltext@MSK | Save

Iomab with adoptive cellular therapy (Iomab-ACT): A pilot study of 131-I apamistamab followed by CD19-targeted car T-cell therapy for patients with relapsed or refractory B-cell acute lymphoblastic leukemia or diffuse large B-cell lymphoma

Meeting Abstract

Geyer, M. B.; Cadzin, B.; Halton, E.; Kane, P.; Senechal, B.; Geoghegan, E. M.; Reddy, V.; Berger, M. S.; Ludwig, D.; Pandit-Taskar, N.; more...
Blood (2021)

Fulltext@MSK | Save